Savara, Inc. (SVRA)
| Market Cap | 195.50M |
| Revenue (ttm) | 257,000 |
| Net Income (ttm) | -49.62M |
| Shares Out | 59.31M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $1.75 |
| Previous Close | $1.68 |
| Change ($) | 0.07 |
| Change (%) | 4.17% |
| Day's Open | 1.68 |
| Day's Range | 1.60 - 1.79 |
| Day's Volume | 2,414,222 |
| 52-Week Range | 1.00 - 3.58 |
While penny stocks are always incredibly risky ventures, these publicly traded companies offer interesting catalysts to consider. The post 7 Penny Stocks with Interesting Catalysts appeared first on Inv...
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Retail investors over on Reddit Penny Stocks are showing interest in quite a few interesting players today that investors will want to note. The post 7 Reddit Penny Stocks Seeing the Most Chatter Today ...
Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.
Savara Inc. (NASDAQ:SVRA) shares rallied Tuesday after Piper Sandler initiated coverage of the stock with an Overweight rating and $7 price target.
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the closing of its previously announced underwritten public offering of 57,479,978 shares of i...
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 45,785,828 shares of its common stock at a p...
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in...
Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on changes to the Company's pipeline, leadership, and business operations that are be...
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara Management will participate in virtual fireside chats at the following investor he...
Savara is a rare lung disease company whose lead asset, Molgradex, failed to meet its primary endpoint in the Phase 3 IMPALA trial. Since that time, Savara has met with the FDA and has designed a new Ph...
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Matthew Pauls, Chairman and Interim CEO, will be presenting at the Jefferies Virtual Lond...
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2020 and provided a business updat...
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Officer (CEO) and from the Boar...
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C.
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM.
Savara (SVRA) to halt the ENCORE study on its lead candidate Molgradex, which was meant to treat nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis.
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the decision to discontinue ENCORE, a 48-week, open-label, non-controlled Phase 2a exploratory...
Savara has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Savara Inc (SVRA) CEO Robert Neville on Q2 2020 Results - Earnings Call Transcript
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the second quarter ending June 30, 2020 and provided a business update.
Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the virtual Canaccord...
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2020 financial results and provide a business upda...
Many believe that the market does not accurately the current state of our economy. With double-digit unemployment and Q2 earnings expected to disappoint, the stock market is rich with several Top Shorts...
Savara Inc. (SVRA) CEO Rob Neville on Q1 2020 Results - Earnings Call Transcript
Savara has been struggling lately, but the selling pressure may be coming to an end soon.
Savara Inc. (SVRA) CEO Rob Neville on Q4 2019 Results - Earnings Call Transcript
Savara (SVRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.
Savara Inc. (NASDAQ: SVRA) shares more than doubled on Monday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its autoimmune pu...
These companies have a low financial burden.
Shares of Savara Inc. SVRA, -6.42% tumbled 48% in premarket trade Wednesday, after the orphan lung disease company said the U.S.
Savara Inc. (SVRA) CEO Rob Neville on Q2 2019 Results - Earnings Call Transcript
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
A host of factors pulled some stocks down.
Investors just received some bad news about the company's lead drug candidate.
Shares of the thinly traded small-cap biotech Savara Inc (NASDAQ: SVRA) were plunging to a record low Thursday in the wake of a clinical trial readout from the company.
Savara Inc. (NASDAQ: SVRA) shares were absolutely crushed on Thursday after the company released its late-stage results for its treatment of autoimmune pulmonary alveolar proteinosis (aPAP).
Savara's (SVRA) lead pipeline candidate, Molgradex, fails to meet primary endpoint in a phase III study evaluating it in a rare autoimmune lung disorder.
Shares in Savara Inc., which is seeking to address rare lung diseases, dropped 75% in after-hours trading Wednesday, when the drug company announced that a study failed to hit its target.
Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.
Savara Inc (SVRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Savara Inc. (SVRA) CEO Rob Neville on Q1 2019 Results - Earnings Call Transcript
Savara Inc. (SVRA) CEO Rob Neville on Q4 2018 Results - Earnings Call Transcript
About SVRA
Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
| Industry Biotechnology | |
| CEO Robert Neville | Employees 27 |
| Stock Exchange NASDAQ | Ticker Symbol SVRA |
Analyst Forecasts
According to 4 analysts, the average rating for Savara stock is "Buy." The 12-month stock price forecast is 3.80, which is an increase of 117.14% from the latest price.